BACKGROUND: The objective was to evaluate the performance (in terms of accuracy, precision, and trueness) of 5 CE-certified and commercially available blood glucose (BG) systems (meters plus test strips) using an innovative clinical-experimental study design with a 3-step glucose clamp approach and frequent capillary BG measurements. METHODS: Sixteen subjects with type 1 diabetes participated in this open label, single center trial. BG was clamped at 3 levels for 60 minutes each: 60-100-200 mg/dL. Medical staff performed regular finger pricks (up to 10 per BG level) to obtain capillary blood samples for paired BG measurements with the 5 BG systems and a laboratory method as comparison. RESULTS: Three BG systems displayed significantly lower mean absolute relative deviations (MARD) (ACCU-Chek® Aviva Nano [5.4%], BGStar® [5.1%], iBGStar® [5.3%]) than 2 others (FreeStyle InsuLinx® [7.7%], OneTouch Verio®IQ [10.3%]). The measurement precision of all BG systems was comparable, but relative bias was also lower for the 3 systems with lower MARD (ACCU-Chek [1.3%], BGStar [-0.9%], iBGStar [1.0%]) compared with the 2 others (FreeStyle [-7.2%], OneTouch [8.9%]). CONCLUSIONS: This 3 range glucose clamp approach enables a systematic performance evaluation of BG systems under controlled and reproducible conditions. The random error of the tested BG systems was comparable, but some showed a lower systematic error than others. These BG systems allow an accurate glucose measurement at low, normal and high BG levels.
BACKGROUND: The objective was to evaluate the performance (in terms of accuracy, precision, and trueness) of 5 CE-certified and commercially available blood glucose (BG) systems (meters plus test strips) using an innovative clinical-experimental study design with a 3-step glucose clamp approach and frequent capillary BG measurements. METHODS: Sixteen subjects with type 1 diabetes participated in this open label, single center trial. BG was clamped at 3 levels for 60 minutes each: 60-100-200 mg/dL. Medical staff performed regular finger pricks (up to 10 per BG level) to obtain capillary blood samples for paired BG measurements with the 5 BG systems and a laboratory method as comparison. RESULTS: Three BG systems displayed significantly lower mean absolute relative deviations (MARD) (ACCU-Chek® Aviva Nano [5.4%], BGStar® [5.1%], iBGStar® [5.3%]) than 2 others (FreeStyle InsuLinx® [7.7%], OneTouch Verio®IQ [10.3%]). The measurement precision of all BG systems was comparable, but relative bias was also lower for the 3 systems with lower MARD (ACCU-Chek [1.3%], BGStar [-0.9%], iBGStar [1.0%]) compared with the 2 others (FreeStyle [-7.2%], OneTouch [8.9%]). CONCLUSIONS: This 3 range glucose clamp approach enables a systematic performance evaluation of BG systems under controlled and reproducible conditions. The random error of the tested BG systems was comparable, but some showed a lower systematic error than others. These BG systems allow an accurate glucose measurement at low, normal and high BG levels.
Authors: Sanja Ramljak; Petra B Musholt; Christina Schipper; Frank Flacke; Jochen Sieber; Marcus Borchert; Thomas Forst; Andreas Pfützner Journal: Expert Opin Med Diagn Date: 2013-10-03
Authors: Andreas Pfützner; Michael Mitri; Petra B Musholt; Daniela Sachsenheimer; Marcus Borchert; Andrew Yap; Thomas Forst Journal: Curr Med Res Opin Date: 2012-03-21 Impact factor: 2.580
Authors: Omar Rana; Christopher D Byrne; David Kerr; David V Coppini; Soha Zouwail; Roxy Senior; Joe Begley; Jeremy J Walker; Kim Greaves Journal: Circulation Date: 2011-09-12 Impact factor: 29.690
Authors: Rohana J Wright; David E Newby; David Stirling; Christopher A Ludlam; Ian A Macdonald; Brian M Frier Journal: Diabetes Care Date: 2010-07 Impact factor: 17.152
Authors: Catherine A Sheffield; Michael P Kane; Gary Bakst; Robert S Busch; Jill M Abelseth; Robert A Hamilton Journal: Diabetes Technol Ther Date: 2009-09 Impact factor: 6.118
Authors: Linda E Thomas; Michael P Kane; Gary Bakst; Robert S Busch; Robert A Hamilton; Jill M Abelseth Journal: Diabetes Technol Ther Date: 2008-04 Impact factor: 6.118